Please ensure Javascript is enabled for purposes of website accessibility

Regeneron's Immunotherapy Is Given Priority Review for Treatment of New Lung Cancer Patients

By Cory Renauer – Updated Oct 29, 2020 at 5:34PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The FDA has accepted an application that could expand Libtayo's addressable patient population to include an important niche.

The Food and Drug Administration on Thursday accepted an application from Regeneron (REGN 4.25%) that could make Libtayo a new treatment option for a specific group of freshly diagnosed lung cancer patients in six months or less. Libtayo is one of several antibodies Sanofi (SNY -2.58%) markets in partnership with Regeneron. 

The agency has agreed to a priority review of Regeneron's application for the treatment of first-line non-small cell lung cancer (NSCLC) patients with tumor cells that express Libtayo's target, PD-L1, at least half of the time. The agency set an action date for Feb. 28, 2021, which is four months sooner than it would have been without priority status.

Two scientists working in a laboratory.

Image source: Getty Images.

During a clinical trial underpinning Regeneron's application, treatment with Libtayo as a monotherapy reduced the risk of death by 32% for patients with tumors that express high levels of PD-L1. That risk reduction increased to 43% compared with standard chemotherapy for patients with PD-L1 present on at least 50% of their tumor cells.

In 2018, Libtayo became the sixth drug of its class to earn at least one FDA approval, but this hasn't prevented it from generating impressive sales as the first and only treatment approved specifically for patients with advanced-stage cutaneous squamous cell carcinoma (CSCC). The FDA granted Libtayo its first approval in 2018, and it finished the first half of 2020 on pace to reach $320 million.

Far more patients have advanced-stage lung cancer than CSCC, but Libtayo will run into stiff competition for first-line NSCLC patients from Merck's (MRK -0.50%) mega-blockbuster PD-1 drug, Keytruda. Sales of Keytruda have soared to an annualized $14.8 billion during the third quarter since earning approval to treat first-line NSCLC patients in 2018.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.